IDEXX Noncontrolling Interest In Consolidated Entity from 2010 to 2024
| IDXX Stock | USD 506.38 1.28 0.25% |
Noncontrolling Interest In Consolidated Entity | First Reported 2010-06-30 | Previous Quarter 763 K | Current Value 706 K | Quarterly Volatility 210.1 K |
Check IDEXX Laboratories financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IDEXX Laboratories' main balance sheet or income statement drivers, such as Depreciation And Amortization of 120.7 M, Interest Expense of 37.7 M or Total Revenue of 3.8 B, as well as many indicators such as Price To Sales Ratio of 13.22, Dividend Yield of 0.0 or PTB Ratio of 32.61. IDEXX financial statements analysis is a perfect complement when working with IDEXX Laboratories Valuation or Volatility modules.
IDEXX | Noncontrolling Interest In Consolidated Entity |
Latest IDEXX Laboratories' Noncontrolling Interest In Consolidated Entity Growth Pattern
Below is the plot of the Noncontrolling Interest In Consolidated Entity of IDEXX Laboratories over the last few years. It is IDEXX Laboratories' Noncontrolling Interest In Consolidated Entity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in IDEXX Laboratories' overall financial position and show how it may be relating to other accounts over time.
| Noncontrolling Interest In Consolidated Entity | 10 Years Trend |
|
Noncontrolling Interest In Consolidated Entity |
| Timeline |
IDEXX Noncontrolling Interest In Consolidated Entity Regression Statistics
| Arithmetic Mean | 343,183 | |
| Geometric Mean | 176,815 | |
| Coefficient Of Variation | 93.47 | |
| Mean Deviation | 277,420 | |
| Median | 264,000 | |
| Standard Deviation | 320,778 | |
| Sample Variance | 102.9B | |
| Range | 839.7K | |
| R-Value | 0.95 | |
| Mean Square Error | 11.5B | |
| R-Squared | 0.90 | |
| Slope | 67,915 | |
| Total Sum of Squares | 1.4T |
IDEXX Noncontrolling Interest In Consolidated Entity History
About IDEXX Laboratories Financial Statements
IDEXX Laboratories investors use historical fundamental indicators, such as IDEXX Laboratories' Noncontrolling Interest In Consolidated Entity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in IDEXX Laboratories. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Noncontrolling Interest In Consolidated Entity | 813 K | 853.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.